Death caused by asthma is not traditionally thought to be especially common, but it is important to note that asthma often plays a contributing and probably unrecognized role even if it is not often listed as the cause of death on a death certificate. Because early response to asthma exacerbations can make a crucial difference, it is important to develop patient action plans in the outpatient setting well before an attack occurs. However, since busy clinicians must prioritize their educational efforts, identifying who is most at risk for death from asthma is all the more important.
Death caused by asthma is not traditionally thought to be especially common, but it is important to note that asthma often plays a contributing and probably unrecognized role even if it is not often listed as the cause of death on a death certificate. Because early response to asthma exacerbations can make a crucial difference, it is important to develop patient action plans in the outpatient setting well before an attack occurs. However, since busy clinicians must prioritize their educational efforts, identifying who is most at risk for death from asthma is all the more important.
Aside from the more general risk factors of age, education, and socioeconomic status, more specific factors must be kept in mind when treating patients with asthma. The first and most intuitive risk factor is the severity of asthma, but there is controversy about how to best gauge this. This uncertainty stems from the fact that there are few prospective studies on asthma mortality; thus, few studies show that one measure of asthma severity is better than another in predicting death. Forced expiratory volume in 1 second (FEV1) and peak flow are each predictive of death, with a 25% drop in FEV1 (as a percentage of the predicted value) conferring about a 2-fold higher risk of all-cause mortality in patients with asthma.1
Even in the absence of spirometric information, however, severity as assessed by dyspnea, asthma medication use, and previous asthma-related hospitalizations or intubations provides good insight into the risk of death. An asthma severity score developed at the University of California at San Francisco incorporates these items and has been shown prospectively to be predictive of death.2,3 The staging system used in the Global Initiative on Asthma guidelines appears reasonable to use as a measure of severity, but it specifically has not been shown to predict death.4
Another important risk factor is tobacco use. Although we typically think of chronic obstructive pulmonary disease in connection with smoking and obstructive lung disease, patients with asthma smoke at approximately the same rates as the general population, and smoking significantly increases their risk of death.5 I emphasize this because cross-sectional studies have suggested that tobacco smoking may decrease the risk of asthma,6 and it is not uncommon for patients to insist that their asthma symptoms developed after they stopped smoking.7
However, better research has demonstrated that smoking worsens asthma.8,9 In fact, the observation of higher rates of death in former smokers is explained by the "healthy smoker" effect, whereby patients who are sicker tend to quit smoking because they are sicker, thus leaving the healthier patients behind. When taking into account this general health effect, we see that quitting tobacco reduces the risk of death from asthma.
Finally, race must be mentioned as a possible risk factor. However, the evidence here is murky. Most studies on race as a risk factor have been retrospective and have not been able to adjust for socioeconomic status or health care access.10 These retrospective studies have shown that asthma mortality rates for African Americans are about 5-fold higher than in other racial groups. However, African Americans were not at increased risk for longer-term death in one population of insured adults who were hospitalized for asthma and survived to discharge.2 Although the jury is still out on this question, it appears reasonable for now to focus on such factors as socioeconomic status, health literacy, social support, and insurance status rather than on race specifically in deciding who is most at risk for asthma-related death.
REFERENCES
1.
Hansen EF, Vestbo J, Phanareth K, et al. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;163:690-693.
2.
Omachi TA, Iribarren C, Sarkar U, et al. Risk factors for death in adults with severe asthma.
Ann Allergy Asthma Immunol.
2008;101:130-136.
3.
Eisner MD, Katz PP, Yelin EH, et al. Assessment of asthma severity in adults with asthma treated by family practitioners, allergists, and pulmonologists.
Med Care.
1998;36:1567-1577.
4.
National Institutes of Health, US Department of Health and Human Services. Global strategy for asthma management and prevention.
WHO/NHLBI workshop report.
Bethesda, MD: National Institutes of Health; National Heart, Lung, and Blood Institute; 1995. NIH publication 95-3659.
5.
Eisner MD, Yelin EH, Trupin L, Blanc PD. Asthma and smoking status in a population-based study of California adults.
Public Health Rep.
2001;116:148-157.
6.
Hjern A, Hedberg A, Haglund B, Rosén M. Does tobacco smoke prevent atopic disorders? A study of two generations of Swedish residents.
Clin Exp Allergy.
2001;31:908-914.
7.
Godtfredsen NS, Lange P, Prescott E, et al. Changes in smoking habits and risk of asthma: a longitudinal population based study.
Eur Respir J.
2001;18:549-554.
8.
Rasmussen F, Siersted HC, Lambrechtsen J, et al. Impact of airway lability, atopy, and tobacco smoking on the development of asthma-like symptoms in asymptomatic teenagers.
Chest.
2000;117:1330-1335.
9.
Plaschke PP, Janson C, Norrman E, et al. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking.
Am J Respir Crit Care Med.
2000;162:920-924.
10.
Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia from 1969 to 1991.
N Engl J Med.
1994; 331:1542-1546.
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
2 Commerce Drive
Cranbury, NJ 08512